The Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania
Bipolar Disorder
About this trial
This is an interventional treatment trial for Bipolar Disorder focused on measuring Bipolar, risperidone, Adjunctive therapy
Eligibility Criteria
Inclusion Criteria: In- or out-patient Diagnosis of bipolar I disorder most recent episode manic with or without psychotic features YMRS > 20 (manic) Need antipsychotic combination on the basis of clinicians' experience Exclusion Criteria: Rapid cycling Risk of suicide or violence History of Substance dependence within 3 months Comorbidities Unstable medical illness Previous sensitivity history to risperidone Pregnant woman or those without proper contraception History of clozapine and one cycle of depot use prior to entry History of treatment resistance: at least two mood stabilizers Prior history of active treatment with risperidone As for patients having wash-out period, patients that show 25% or more decrease in YMRS at baseline as compared to that at enrollment time, should be excluded.